3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
152
Neoplasm Metastasis
22
Neoplasms
21
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Breast Diseases
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
binimetinib
2
Sodium Chloride
2
Aminolevulinic Acid
2
palbociclib
1
methyl 5-aminolevulinate
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Fluorouracil
1
Floderm topical cream
1
Everolimus
1
Equipment and Supplies
1
Docetaxel
1
Dacarbazine
1
Cetuximab
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Diseases
×
palbociclib
×
Clear all
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled